Contribute Try STAT+ Today

Americans with private employer health insurance spent nearly 26% more on prescription drugs from 2014 to 2018, according to a new analysis. At the same time, the average price of a medicine purchased by each employee rose by almost 21% and their usage rose more than 4% during that time period.

Moreover, the rate at which prescription drug spending rose also outpaced the increased cost of other medical services, such as doctor visits and hospital admissions, during those five years. On a year-over-year basis, prescription drug spending per person rose 4.7% in 2018, although the rate of growth declined from 2014. Notably, usage rose a modest 1% that year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Ed, To what extent is this about out of pocket costs that patients pay at pharmacy…that is the cost that matters to patients. Having said that, I am a firm supporter of price increase caps to CPI, and transparency on where that increase goes..the avg gross price of insulin has gone up dramatically over past ten years, but the manufacturers net price has gone down, meaning that increase went to the rebate/PBM.

Comments are closed.